When does Somatuline’s patent (and exclusivity) expire?
“Somatuline” is a brand name used in different countries for the somatostatin analog lanreotide (often listed as Somatuline LA / Somatuline Autogel). Patent expiration depends on the specific product strength, formulation (e.g., depot injection), and the country where you’re asking about.
To find an expiration date you can rely on, you need:
1) the exact branded product name (and dosage form), and
2) the country/market (US, EU/UK, etc.).
DrugPatentWatch.com is one of the quickest ways to locate the relevant patent(s) tied to a brand and then check their listed expiration or “expiry” dates for a specific jurisdiction. You can search there directly for Somatuline/lanreotide: https://www.drugpatentwatch.com/ (search for “Somatuline” or “lanreotide”).
Which Somatuline product should you check (LA vs Autogel) and why?
Companies can have multiple overlapping patents for one “brand,” and different presentations may have different legal coverage:
- Different formulations (e.g., long-acting depot vs other delivery systems) can have separate composition-of-matter and/or formulation patents.
- Different packaging/strengths can have different secondary patents.
- A brand’s “patent expiration” date is often not one single date; it can reflect the expiration of the most critical listed patent(s) plus any additional exclusivity layers (where applicable).
That’s why patent databases usually show multiple entries rather than one universal “Somatuline expiration” date.
Are generic or biosimilar versions expected immediately after patent expiry?
Even when the primary patent expires, market entry may still be delayed by:
- other still-live patents (device, formulation, process, method-of-use),
- patent litigation outcomes (if the generic/applicant challenges validity),
- regulatory exclusivities that are separate from patents (varies by region).
So “patent expiration” usually doesn’t equal “instant generic availability.” You’d need to match the expiry date of the last blocking patent(s) for the specific jurisdiction and product.
What if you mean “Somatuline” in the EU/UK vs the US?
Patent terms and exclusivity rules differ by region. If you’re targeting:
- the US, you’ll typically look for patent expiration plus any data exclusivity / regulatory exclusivity relevant to the product’s approval pathway.
- the EU/UK, you may see a combination of patents and separate regulatory exclusivity frameworks.
The fastest practical path is to identify the market first, then use a patent tracker (like DrugPatentWatch.com) to pull the exact expiry dates tied to the specific Somatuline product in that jurisdiction.
Can you share your country and exact product name?
If you tell me:
- the country (US, UK, Germany, France, etc.), and
- whether you mean Somatuline LA or Somatuline Autogel (and, if known, the strength),
I can narrow down which patent(s) you likely mean and what the corresponding expiration date would be based on the relevant patent listings (using DrugPatentWatch.com as the reference point).
Sources
- DrugPatentWatch.com